{"id":3944,"date":"2025-03-31T18:11:53","date_gmt":"2025-03-31T18:11:53","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/epirubicin-hydrochloride-txt\/"},"modified":"2025-03-31T18:11:53","modified_gmt":"2025-03-31T18:11:53","slug":"epirubicin-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/epirubicin-hydrochloride-txt\/","title":{"rendered":"Epirubicin hydrochloride.txt"},"content":{"rendered":"

Epirubicin hydrochloride<\/h1>\n

CLINICAL USE <\/H3>
\nAntineoplastic agent:Leukaemias Malignant lymphomas Multiple myeloma Various solid tumours

DOSE IN NORMAL RENAL FUNCTION <\/H3>60\u201390 mg\/m2 every 3 weeksHigh dose: 100\u2013135 mg\/m2 every 3\u20134 weeks,or 45 mg\/m2 on days 1, 2, and 3, every 3 weeksOr according to local protocol

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :580<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :77<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 9\u201310<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :14\u201338<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :30\u201340\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function, but use lower dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antipsychotics: avoid concomitant use with clozapine \u2013 increased risk of agranulocytosis\n
  • Ciclosporin: increased risk of neurotoxicity\n
  • Ulcer-healing drugs: concentration reduced by cimetidine

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Reconstitute with water for injection or sodium chloride 0.9% (rapid dissolution only)

    Route <\/H4>IV, intravesical (bladder instillation), intrathecal

    Rate of Administration <\/H4>IV: give via the tubing of a fast running intravenous infusion of sodium chloride 0.9% or glucose 5%, taking 3\u20135 minutes over the injection

    IV infusion <\/H4>: 30 minutes

    Comments<\/H4>For bladder instillation: concentration of epirubicin in bladder should be 50\u201380 mg per 50 mL once a week. To avoid undue dilution in urine, the patient should be instructed not to drink any fluid in the 12 hours prior to instillationIn the case of local toxicity dose is reduced to 30 mg per 50 mL

    OTHER INFORMATION <\/H4>A cumulative dose of 900\u20131000 mg\/m 2 should only be exceeded with extreme caution. Above this level, the risk of irreversible congestive cardiac failure increases greatlyMainly metabolised in the liver; 27\u201340% eliminated by biliary excretion. Slow elimination through the liver is due to extensive tissue distribution. Urinary excretion accounts for approximately 10% of the dose in 48 hrsPatients with impaired hepatic function have prolonged and elevated plasma concentrations of epirubicin \u2013 dose reduction is requiredEpirubicin may make the urine red for 1\u20132 days after administration
    \n","protected":false},"excerpt":{"rendered":"

    Epirubicin hydrochloride CLINICAL USE Antineoplastic agent:Leukaemias Malignant lymphomas Multiple myeloma<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3944","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3944"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3944\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}